Evolus Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(949 ) 284-4555
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
(Nasdaq Global Market) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed by Evolus, Inc. (the “Company”) in a Current Report on Form 8-K filed with the SEC on April 3, 2024, Simone Blank voluntarily stepped down from the board of directors of the Company (the “Board”) effective on June 5, 2025, as part of a planned board refreshment and transition.
As a result of Ms. Blank’s departure, effective on June 5, 2025, Albert White III will serve on the Audit Committee of the Board.
Ms. Blank’s planned transition did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 5, 2025, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2025. The results for each matter voted on by the stockholders at the Annual Meeting were as follows:
Proposal 1: The stockholders of the Company elected each of David Gill and Albert White III as Class I Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2028 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the Class I Directors were as follows:
Nominee | Term Expiring | For | Withhold | Broker Non-Vote | ||||||||||
David Gill | 2028 | 31,501,028 | 5,607,409 | 11,441,970 | ||||||||||
Albert White III | 2028 | 36,789,320 | 319,117 | 11,441,970 | ||||||||||
Proposal 2: The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The results of the stockholders’ vote with respect to such ratification were as follows:
For | Against | Abstain | ||||||
48,353,514 | 189,695 | 7,198 | ||||||
Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of the stockholders’ vote with respect to the approval, on an advisory basis of the Company's named executive officers were as follows:
For | Against | Abstain | Broker Non-Vote | ||||||||
35,679,157 | 1,232,290 | 196,990 | 11,441,970 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolus, Inc. | ||||||||
Dated: June 6, 2025 | /s/ David Moatazedi | |||||||
David Moatazedi | ||||||||
President and Chief Executive Officer | ||||||||